Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women

Yonsei Medical Journal

Volumn 51, Issue 2, 2010, Pages 231-238

  Choi, Hyung Jin ^a   Choi, Ji Yeob ^b   Cho, Sun Wook ^a   Kang, Daehee ^a   Han, Ki Ok ^c   Kim, Sang Wan ^a   Kim, Seong Yeon ^a   Chung, Yoon Sok ^d   Shin, Chan Soo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Kwandong University College of Medicine   (South Korea)

^d Ajou University School of Medicine   (South Korea)

Author keywords

Bisphosphonate; Osteoporosis; Polymorphism

Indexed keywords

ALENDRONIC ACID; CALCIUM; FARNESYL TRANS TRANSFERASE; RISEDRONIC ACID; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; CONTROLLED STUDY; FEMALE; FEMUR NECK; GENE DELETION; GENE INSERTION; GENOTYPE; HIGH RISK POPULATION; HUMAN; KOREA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MORNING DOSAGE; OSTEOPOROSIS; PREDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIMETHYLALLYLTRANSTRANSFERASE; DIPHOSPHONATES; FARNESYLTRANSTRANSFERASE; FEMALE; GERANYLTRANSTRANSFERASE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 77649202953     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2010.51.2.231     Document Type: Article

References (26)

1. Eisman JA. Genetics of osteoporosis. Endocr Rev 1999;20:788-804.
2. Sainz J, Van Tornout JM, Loro ML, Sayre J, Roe TF, Gilsanz V. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. N Engl J Med 1997;337:77-82.
3. Uitterlinden AG, Burger H, Huang Q, Yue F, McGuigan FE, Grant SF, et al. Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med 1998;338:1016-21.
4. Mann V, Hobson EE, Li B, Stewart TL, Grant SF, Robins SP, et al. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest 2001;107:899-907.
5. Mizunuma H, Hosoi T, Okano H, Soda M, Tokizawa T, Kagami I, et al. Estrogen receptor gene polymorphism and bone mineral density at the lumbar spine of pre- and postmenopausal women. Bone 1997;21:379-83.
6. Keen RW, Woodford-Richens KL, Lanchbury JS, Spector TD. Allelic variation at the interleukin-1 receptor antagonist gene is associated with early postmenopausal bone loss at the spine. Bone 1998;23:367-71.
7. Tsukamoto K, Yoshida H, Watanabe S, Suzuki T, Miyao M, Hosoi T, et al. Association of radial bone mineral density with CA repeat polymorphism at the interleukin 6 locus in postmenopausal Japanese women. J Hum Genet 1999;44:148-51.
8. Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF. A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 1997;20:289-94.
9. Keen RW, Snieder H, Molloy H, Daniels J, Chiano M, Gibson F, et al. Evidence of association and linkage disequilibrium between a novel polymorphism in the transforming growth factor beta 1 gene and hip bone mineral density: a study of female twins. Rheumatology (Oxford) 2001;40:48-54.
10. Kurland ES, Rosen CJ, Cosman F, McMahon D, Chan F, Shane E, et al. Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1997;82:2799-805.
11. Masi L, Becherini L, Colli E, Gennari L, Mansani R, Falchetti A, et al. Polymorphisms of the calcitonin receptor gene are associated with bone mineral density in postmenopausal Italian women. Biochem Biophys Res Commun 1998;248:190-5.
12. Shiraki M, Shiraki Y, Aoki C, Hosoi T, Inoue S, Kaneki M, et al. Association of bone mineral density with apolipoprotein E phenotype. J Bone Miner Res 1997;12:1438-45.
13. Johnson ML, Gong G, Kimberling W, Reckér SM, Kimmel DB, Recker RB. Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13). Am J Hum Genet 1997;60:1326-32.
14. Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 2006;39:1268-75.
15. Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SM, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006;91:2631-7.
16. Lewiecki EM. Nonresponders to osteoporosis therapy. J Clin Densitom 2003;6:307-14.
17. Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, et al. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 2005;52: 667-74.
18. Crilly RG, Sebaldt RJ, Hodsman AB, Adachi JD, Brown JP, Goldsmith CH, et al. Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis. Osteoporos Int 2000;11:607-14.
19. Qureshi AM, Herd RJ, Blake GM, Fogelman I, Ralston SH. COLIA 1 Sp 1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcif Tissue Int 2002;70:158-63.
20. Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, et al. Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes. Clin Endocrinol (Oxf) 2003;58:365-71.
21. Palomba S, Orio F Jr, Russo T, Falbo A, Tolino A, Manguso F, et al. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int 2005;16:943-52.
22. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-41.
23. Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, et al. Bisphosphonates target multiple sites in both cis- and transprenyltransferases. Proc Natl Acad Sci U S A 2007;104:10022-7.
24. Turner CH. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002;13:97-104.
25. Silverman SL. Management of corticosteroid-induced osteoporosis: a clinician's perspective. Calcif Tissue Int 1992;50:101-3.
26. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006;119(4 Suppl 1):S25-31.